Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;28(11):2084-7.
doi: 10.1002/stem.513.

Concise review: stem cells as an emerging platform for antibody therapy of cancer

Richard T Frank  1 , Joseph Najbauer, Karen S Aboody
Affiliations
Free PMC article
Review

Concise review: stem cells as an emerging platform for antibody therapy of cancer

Richard T Frank et al. Stem Cells. 2010 Nov.
Free PMC article

Abstract

Monoclonal antibodies are important tools for cancer therapy, however, three factors limit their effectiveness: toxicity, poor tumor penetration, and inability to cross the blood-brain barrier. This review discusses the emerging field of stem cell-mediated antibody delivery and how this approach may improve antibody therapy of cancer by overcoming these obstacles.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Strategies for stem cell-based antibody therapy of cancer. Models of potential strategies for the use of stem cells in antibody therapy. Delivery of antibodies or antibody-like molecules directly to tumor by tumor-tropic stem cells expressing either secreted antibody (A) or cell surface-bound antibody (B). Use of stem cells as “biological pumps” to secrete antibodies or antibody-like molecules into the bloodstream (C). All strategies utilize unique properties of stem cells to overcome limitations of traditional antibody therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147–1157. - PubMed
    1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357. - PubMed
    1. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008;15:739–752. - PubMed
    1. Najbauer J, Danks MK, Schmidt NO, et al. Neural stem cell-mediated therapy of primary and metastatic solid tumors. In: Bertolotti R, Ozawa K, editors. Progress in Gene Therapy, Autologous and Cancer Stem Cell Gene Therapy. Singapore: World Scientific; 2007. pp. 335–372.
    1. Kendall SE, Najbauer J, Johnston HF, et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells. 2008;26:1575–1586. - PubMed